Arvinas (ARVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 24, 2026, with voting on director elections, executive compensation, and auditor ratification.
Only shareholders of record as of April 27, 2026, are eligible to vote; 64,517,472 shares were outstanding as of that date.
Proxy materials are distributed electronically to reduce costs and environmental impact, with options for printed copies upon request.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class II directors for three-year terms, a non-binding advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
The board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by December 30, 2026, or nominate directors per advance notice bylaws.
Board of directors and corporate governance
The board is divided into three classes with staggered terms; after the meeting, it will have eight members.
Nominees for Class II are Leslie V. Norwalk, Esq. and Randy Teel, Ph.D.; Sunil Agarwal, M.D. is not standing for re-election.
The board has audit, compensation, nominating/governance, and science/technology committees, all with independent members except for the CEO.
Corporate governance guidelines, code of conduct, and insider trading policy are in place; annual board self-evaluations are conducted.
Latest events from Arvinas
- FDA approval and out-licensing of VEPPANU drove record Q2 revenue and net income.ARVN
Q2 2026 - Phase III vepdegestrant data and new combination results are set to drive multiple launches and pipeline growth.ARVN
2024 Cantor Fitzgerald Global Healthcare Conference - All voting items passed at the virtual meeting, with no shareholder questions submitted.ARVN
AGM 2026 - First PROTAC approval, focused pipeline, and key clinical milestones ahead in PSP and SBMA.ARVN
Jefferies Global Healthcare Conference 2026 - FDA approved VEPPANU, the first PROTAC degrader, amid Q1 net loss and strong cash reserves.ARVN
Q1 2026 - Votes will be held on director elections, executive pay, and auditor ratification at the 2026 meeting.ARVN
Proxy filing - Improved financials and pipeline progress set stage for key 2026 milestones and FDA review.ARVN
Q4 2025 - Vepdegestrant improved median PFS by 2.9 months over fulvestrant in ESR1-mutant breast cancer.ARVN
Study Update - Q1 2025 saw revenue and net income surge, with restructuring extending cash runway into 2H 2028.ARVN
Q1 2025